Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

David Hoenig

Urology Lake Success, NY Medical Doctor

NPI 1457467086 CMS profile 293016

450 Lakeville Road, Suite M41, Smith Institute For Urology, Lake Success, NY 11042

Open in the dashboard

General payments

$874

5 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$13,790 paid to institutions, not to them · program year 2023

Through program year 2025, David Hoenig of Lake Success, NY is reported in the CMS Open Payments database as having received $874 across 5 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $13,790 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 30th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $136 1
2024 General $114 1
2022 General $600 1
2021 General $24 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Hoenig
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to David Hoenig were reported at $136. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year David Hoenig Urology median Middle half National median
2019 $0 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $24 $358 $111–$1,000 $132
2022 $600 $476 $143–$1,263 $149
2023 $0 $560 $168–$1,461 $160
2024 $114 $563 $170–$1,464 $164
2025 $136 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Urogen Pharma, Inc. $624 3 payments
  2. Calyxo, Inc. $136 1 payment
  3. Novo Nordisk Health Care AG $114 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $600 1 payment
  2. Food and Beverage $250 2 payments
  3. Education $24 2 payments
Products named General payments · program years 2021–2025
  1. JELMYTO $624 3 payments
  2. CVAC ASPIRATION SYSTEM $136 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,378

Median for Urology: 1,053

Drug cost

$105,703

Median for Urology: $101,464

Branded share of claims

37.2%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Potassium Citrate Er Potassium Citrate Brand 307 $43,793
Myrbetriq Mirabegron Brand 30 $34,209
Methenamine Hippurate Generic 88 $10,814
Tamsulosin Hcl Generic 324 $5,181
Estradiol Generic 47 $4,139
Finasteride Generic 239 $3,083
Oxybutynin Chloride Er Oxybutynin Chloride Brand 43 $1,358
Allopurinol Generic 56 $605
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 27 $485
Chlorthalidone Generic 21 $443

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$163,578

Medicare's payments for the services billed

Medicare patients

584

Average age 74

Services billed

1,821

196 women, 388 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 45%
Ischemic heart disease 42%
Chronic kidney disease 26%
Cancer 22%
Depression 20%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

5 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record